Investigational drug · Phase 2
BI 754111
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Neoplasm Metastasis, Advanced Tumors, Metastatic Solid Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
5
Any phase or sponsor naming "BI 754111"
First trial start
2019
Mar 19, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BI 754111", any sponsor or status.
Conditions studied
As listed on its trial records.
- Neoplasm Metastasis
- Advanced Tumors
- Metastatic Solid Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "BI 754111" as an intervention, largest first.
- Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid TumoursPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT03697304 · 211 participants · Start Mar 19, 2019 · Primary completion Dec 3, 2024
Drug: Ezabenlimab; BI 754111 and 1 more · For: Neoplasm Metastasis; Advanced Tumors; Metastatic Solid Tumors
Sites: La Jolla, California; Fort Myers, Florida; St. Petersburg, Florida · 17 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT03156114 · 172 participants · Start Jun 13, 2017 · Primary completion Mar 9, 2023
Drug: Ezabenlimab; BI 754111 · For: Neoplasms; Carcinoma, Non-Small-Cell Lung
Sites: Miami, Florida; Sarasota, Florida; Hackensack, New Jersey · 15 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT03433898 · 146 participants · Start Feb 23, 2018 · Primary completion Jul 20, 2023
Drug: Ezabenlimab; BI 754111 · For: Neoplasms
Sites: Chiba, Kashiwa, Japan; Kanagawa, Yokohama, Japan; Saitama, Kitaadachi-gun, Japan · 13 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT03964233 · 119 participants · Start Jun 20, 2019 · Primary completion Sep 5, 2024
Drug: BI 907828; ezabenlimab and 1 more · For: Neoplasms
Sites: Santa Monica, California; New Haven, Connecticut; Athens, Georgia · 23 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT03780725 · 8 participants · Start Jan 22, 2019 · Primary completion Feb 19, 2020
Drug: BI 754111; [89Zr]Zr-BI 754111 and 1 more · For: Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms
Sites: Amsterdam, Netherlands
Newest research
PubMed records naming it or its code names, newest first.
- A minimal physiologically-based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti-LAG-3 monoclonal antibody.
Michelet R, Petersson K, Huisman MC, et al. · CPT Pharmacometrics Syst Pharmacol 2025
- Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series.
Yamamoto N, Tolcher A, Hafez N, et al. · Onco Targets Ther 2024
- 89Zr-immuno-PET using the anti-LAG-3 tracer [89Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC.
Miedema IHC, Huisman MC, Zwezerijnen GJC, et al. · Eur J Nucl Med Mol Imaging 2023
- Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses.
Zettl M, Wurm M, Schaaf O, et al. · Oncoimmunology 2022
Also in development for Neoplasm Metastasis
- OlomorasibLY3537982Phase 36 trials
Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis
- TersolisibLY4064809, STX-478Phase 33 trials
Eli Lilly · Breast Neoplasms, Neoplasm Metastasis, Breast Cancer
- EzabenlimabBI 754091Phase 32 trials
Boehringer Ingelheim · Advanced Cancer, Neoplasm Metastasis, Advanced Tumors
- VepugratinibLY3866288Phase 32 trials
Eli Lilly · Urinary Bladder Neoplasms, Urologic Neoplasms, Receptor, Fibroblast Growth Factor, Type 3
- BI 836880Phase 21 trial
Boehringer Ingelheim · Neoplasm Metastasis, Advanced Tumors, Metastatic Solid Tumors
- IPN60350Phase 21 trial
Ipsen · Neoplasms, Neoplasm Metastasis, Neoplastic Processes
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Boehringer Ingelheim.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.